This is the authors' abstract. We don't add key points for this paper.
Objectives: A rise in peripheral blood of the glycoproteins carcino-embryonic antigen (CEA) and CA15.3 may be indicative of a subsequent clinical relapse and provides a useful adjunct in the management of metastatic breast cancer. We wished to study the relationship of these tumour markers with the expression of keratin 19 (K19) mRNA as a marker of epithelial cancer cells in periodic blood samples taken from patients undergoing postoperative therapy. Methods: CEA and CA15.3 were measured by radio-immunoassay while K19 mRNA was assessed by gel electrophoretic separation after a 40-cycle polymerase chain reaction amplification. Results: Analysis of 395 samples (regardless of patient) showed concurrence in the detection of K19 and CEA and CA15.3 (using positivity cut-offs of 3.2 ng/ml and 32 U/l, respectively) in <20% of cases that were K19+ and in >80% for samples that were K19–. The frequency of CEA and CA15.3 positivity was related to the amount of K19 product. For 65 patients with 2–3 samples collected at 6 monthly intervals, we observed complete agreement for detection of these markers (at each occasion) in about 30% of cases only. Conclusions: These discrepancies may be due partly to the currently qualitative nature of the K19 assessment and emphasize the need for quantification of this but may also reflect a difference in the source of the signals, i.e. K19 originating from circulating cells and CEA/CA15.3 shed from solid tumour deposits. It is likely that K19 detection is more sensitive, but it is less certain which of these markers reflects a significant systemic tumour load and hence is of greater value in predicting relapse.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Luqmani et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: